Product name
Inhibition of micro RNA maturation as new drug targetSummary
miRNA maturation is inhibited by a specifically reduced dicer activityOrganization name
ipal GmbHProfile
A technology which uses Micro RNA (miRNA) inhibition for the treatment of diseases is offered. miRNA maturation is inhibited by a specifically reduced dicer activity. Thus miRNA production is reduced and consequently the pathogenic impact.
The inventor developed a micro RNA maturation assay based on microtiter plate technology to detect potential dicer inhibiting molecules.
Advantages
- Highly innovative technology
- Treatment of diseases with high impact
- Inventors possess knowledge to establish a high throughput assay Application
- Diseases with changed cellular miRNA pattern
- Hepatocellular carcinoma, lung cancer, chronic lymphatic leucemia, thyroid malignancy
- Potential use for treatment of diabetis and neurology
US Patent was filed. The invention was made at the Humboldt University at Berlin and is offered by IPAL.
Contact
IPAL GmbH
Dr. Christian Wunsch
christian.wunsch@ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
07054_miRNA_abstracc5dd3e8a.pdf
print this page
